| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections
|
Alyami, Mohammad H.
|
|
|
30 |
6 |
p.
|
artikel
|
| 2 |
Advancing atherosclerosis treatment: Drug encapsulation nanosystems and synthetic HDL nanoparticles
|
Pedro, Francisca
|
|
|
30 |
6 |
p.
|
artikel
|
| 3 |
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer
|
Zhang, Shengxin
|
|
|
30 |
6 |
p.
|
artikel
|
| 4 |
Artificial intelligence for RNA–ligand interaction prediction: advances and prospects
|
Li, Jing
|
|
|
30 |
6 |
p.
|
artikel
|
| 5 |
Building a human genetic data lake to scale up insights for drug discovery
|
Chatelain, Clement
|
|
|
30 |
6 |
p.
|
artikel
|
| 6 |
Computational methods for modeling protein–protein interactions in the AI era: Current status and future directions
|
Li, Hao
|
|
|
30 |
6 |
p.
|
artikel
|
| 7 |
Current developments in diverse biomaterial formulations for ultrasound-mediated drug delivery
|
Nam, Ji Won
|
|
|
30 |
6 |
p.
|
artikel
|
| 8 |
Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?
|
Boehm, Thomas
|
|
|
30 |
6 |
p.
|
artikel
|
| 9 |
Fexaramine as the intestine-specific farnesoid X receptor agonist: A promising agent to treat obesity and metabolic disorders
|
Dąbrowska, Anna Maria
|
|
|
30 |
6 |
p.
|
artikel
|
| 10 |
Genetic–epigenetic targets for PCOS-associated diabesity
|
Sharma, Arun K.
|
|
|
30 |
6 |
p.
|
artikel
|
| 11 |
Insights from the European Medicines Agency on digital health technology derived endpoints
|
Jadoenathmisier, Keerti D.
|
|
|
30 |
6 |
p.
|
artikel
|
| 12 |
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy
|
Liu, Shuyu
|
|
|
30 |
6 |
p.
|
artikel
|
| 13 |
Navigating the complexities of spinal cord injury: an overview of pathology, treatment strategies and clinical trials
|
Chopra, Manjeet
|
|
|
30 |
6 |
p.
|
artikel
|
| 14 |
NLRP3 inflammasome: From drug target to drug discovery
|
Yin, Ling
|
|
|
30 |
6 |
p.
|
artikel
|
| 15 |
Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics
|
Castanheira, Sara
|
|
|
30 |
6 |
p.
|
artikel
|
| 16 |
Peptide therapy: new promising therapeutics for acute kidney injury
|
Hao, Herui
|
|
|
30 |
6 |
p.
|
artikel
|
| 17 |
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
|
Cornu, Marie
|
|
|
30 |
6 |
p.
|
artikel
|
| 18 |
Synergism or mirage: Current progress and an empirical approach for elucidating combination drug effects
|
Vottero, Paola
|
|
|
30 |
6 |
p.
|
artikel
|
| 19 |
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States
|
Buszkiewicz, Joanna
|
|
|
30 |
6 |
p.
|
artikel
|
| 20 |
Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights
|
Vlček, Přemysl
|
|
|
30 |
6 |
p.
|
artikel
|
| 21 |
The role of cyclic adenosine monophosphate (cAMP) in pathophysiology of fibrosis
|
Harding-Fox, Sophie L.
|
|
|
30 |
6 |
p.
|
artikel
|
Tijdschrift beschrijving